ANIK - NASDAQ
Anika Therapeutics, Inc.
$14.41
+0.49%Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
At a Glance
Live SnapshotAnika Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Anika Therapeutics, Inc. Income Statement
ANIK • NASDAQ
| Anika Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
112.8M | 119.9M | 120.8M | 113.8M | 147.8M | 130.5M | 114.6M | 105.6M | 113.4M | 103.4M | 93M | 105.6M | 75.1M | 71.4M | 64.8M | 55.6M | 40.1M | 35.8M | 30.8M | 26.8M | |
GROSS PROFIT | ||||||||||||||||||||
(49M) | (43.9M) | (38.3M) | (40.6M) | (64.9M) | (61.4M) | (28.7M) | (31.3M) | (27.4M) | (24M) | (21.1M) | (20.9M) | (22.8M) | (29M) | (26.8M) | (23.8M) | (13.7M) | (13.2M) | (11.9M) | (11.1M) | |
63.8M | 76M | 82.5M | 73.2M | 82.9M | 69M | 85.9M | 74.3M | 86.1M | 79.4M | 71.9M | 84.7M | 52.3M | 42.4M | 38M | 31.7M | 26.5M | 22.6M | 18.9M | 15.7M | |
OPERATING INCOME | ||||||||||||||||||||
(74.9M) | (81.1M) | (81.7M) | (69.6M) | (80.3M) | (97.3M) | (51.6M) | (52.5M) | (40.3M) | (28.7M) | (23.8M) | (23.2M) | (20M) | (20.1M) | (24M) | (24.2M) | (18.7M) | (18.4M) | (12.4M) | (10.3M) | |
(49.1M) | (55.6M) | (59.9M) | (51.2M) | (74.1M) | (60.1M) | (35M) | (34.3M) | (21.5M) | (18M) | (14.8M) | (15.1M) | (12.9M) | (14.7M) | (17.9M) | (17.3M) | (10.5M) | (11M) | (8M) | (6.7M) | |
(25.8M) | (25.5M) | (21.8M) | (18.3M) | (27.3M) | (23.4M) | (16.7M) | (18.2M) | (18.8M) | (10.7M) | (9M) | (8.1M) | (7.1M) | (5.4M) | (6.2M) | (6.9M) | (8.2M) | (7.4M) | (4.4M) | (3.6M) | |
-11.1M | -5.1M | 844K | 3.7M | 2.6M | -28.3M | 34.2M | 21.7M | 45.7M | 50.6M | 48.1M | 61.4M | 32.6M | 19.7M | 14M | 7.5M | 5.6M | 4.2M | 6.6M | 5.4M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (800K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (127.2K) | (5.3M) | (182.4K) | (194.6K) | (4.4M) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 2.3M | 654K | 0.0 | -302K | 1.9M | 1.5M | 473K | 263K | 120K | 58K | -127K | -187.8K | -182.4K | -194.6K | -74.5K | 498.5K | 2.1M | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | -21.1M | (13.9M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
1.7M | 2.3M | 2.3M | 654K | -188K | -302K | 1.9M | 1.5M | 473K | 263K | 120K | 58.1K | -127K | -187.8K | -182.4K | -194.6K | -2.2M | 498.5K | 2.1M | 2.1M | |
-9.3M | -2.8M | 3.2M | 4.3M | 2.4M | -28.6M | 36.1M | 23.2M | 46.2M | 50.9M | 48.3M | 61.5M | 32.5M | 19.5M | 13.8M | 7.3M | 5.5M | 4.7M | 8.7M | 7.5M | |
NET INCOME | ||||||||||||||||||||
(672K) | (6.1M) | (6.6M) | (2.1M) | -1.7M | -4.6M | (8.9M) | (4.5M) | (14.4M) | (18.3M) | (17.5M) | (23.2M) | (11.9M) | (7.8M) | (5.3M) | (3M) | (1.8M) | (1.1M) | (2.7M) | (2.9M) | |
-10.9M | -56.4M | -82.7M | -14.9M | 4.1M | -24M | 27.2M | 18.7M | 31.8M | 32.5M | 30.8M | 38.3M | 20.6M | 11.8M | 8.5M | 4.3M | 3.7M | 3.6M | 6M | 4.6M |
SEC Filings
ANIK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 24, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 07, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | July 30, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 30, 2025 | July 30, 2025 | 2025 |
Related Guides
Continue your ANIK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.